Weill Cornell Medical Center, New York-Presbyterian, New York, NY, United States.
Front Endocrinol (Lausanne). 2023 Jan 9;13:1043595. doi: 10.3389/fendo.2022.1043595. eCollection 2022.
While bariatric surgery restults in significant long-term weight loss for most patients with obesity, post-surgical weight gain affects a considerable percentage of patients to varying degrees of severity. Furthermore, a small but significant percentage of patients experience inadequate post-surgical weight loss. Although many studies have examined the role of anti-obesity medications to address post-operative weight regain, an evidence-based consensus has not yet been achieved because of the heterogeneity of populations studied and the studies themselves. Observational studies in the post-bariatric surgery population consistently demonstrate the benefit of medical weight management after bariatric surgery, with most evidence highlighting liraglutide, topiramate, and phentermine/topiramate. New anti-obesity medications are anticipated to be helpful for post-surgical weight optimization given their efficacy in the non-surgical population.
虽然减重手术能使大多数肥胖患者长期显著减重，但术后体重增加会影响相当一部分患者，且严重程度不一。此外，还有一小部分患者术后减重不足。虽然许多研究已经探讨了抗肥胖药物在解决术后体重反弹中的作用，但由于研究人群和研究本身的异质性，尚未达成循证共识。减重手术后人群的观察性研究一致表明，减重手术后进行医学体重管理有益，其中大多数证据强调利拉鲁肽、托吡酯和 phentermine/topiramate。鉴于新的抗肥胖药物在非手术人群中的疗效，预计它们对术后体重优化有帮助。
